Product Pipeline
SBI Biotech strives for novel drug development targeting cancers and autoimmune diseases. We focus on development of molecule targeting drugs and immune modulation drugs with lower side effects and higher efficacies, based on our technologies on DC platform.
Pipeline Overview
| Product Candidate | Indication | Partner |
|---|---|---|
| ILT7 (Daxdilimab/HZN-7734) | DLE,Dermatomyositis | Viela Bio(Amgen) |
| SBI-9674(KK4277) | SLE,CLE | Kyowa Kirin |
| SBI-3150(AK1910) | SLE | Asahi Kasei Pharma |
| Cdc7(AS-0141) | Various cancers | Carna Biosciences, Inc(*) |
(*) SBI Biotech has transferred intellectual property of Cdc7 inhibitor to Carna Biosciences, Inc.(CBS) in 2014.